Pain Pathophysiology and Management

Published on 03/03/2015 by admin

Filed under Neurology

Last modified 22/04/2025

Print this page

rate 1 star rate 2 star rate 3 star rate 4 star rate 5 star
Your rating: none, Average: 0 (0 votes)

This article have been viewed 3527 times

12 Pain Pathophysiology and Management

Neuropathic Pain Syndromes

Neuropathic pain encompasses an array of chronic debilitating nerve injury syndromes that specifically have an adverse impact on the quality of life. To capture the diversity of etiologies, the International Association for the Study of Pain has defined neuropathic pain rather broadly as a “pain initiated or caused by a primary lesion or dysfunction in the nervous system.” These syndromes originate at every level of the neuraxis and include diabetic polyneuropathy, HIV neuropathy, postsurgical pain, postherpetic neuralgia (PHN), trigeminal neuralgia, complex regional pain syndrome (CRPS), spinal cord injury pain, poststroke pain, multiple sclerosis, and phantom limb pain.

Neuropathic pain may be subdivided into two broad neuroanatomic subgroups based on the localization of nerve injury. Central nervous system syndromes result from pathology of the brain and spinal cord such as that associated with a demyelinating plaque in multiple sclerosis or stroke. Peripheral neuropathic pain syndromes are the far more common group and include processes such as reactivation of the varicella-zoster virus giving rise to PHN and painful diabetic polyneuropathy.

Pathophysiology

The understanding of the relationship between the clinical features of neuropathic pain and underlying molecular mechanisms in humans remains in its infancy. Following nerve injury, neuronal remodeling occurs, with microscopic structural changes in the neuronal membrane and individual membrane bound ion channels. Animal models suggest that neuronal remodeling alters the membrane electrical properties, resulting in a state of hyperexcitability wherein thresholds are lowered, action potentials are propagated more easily, and the duration of nerve impulses is prolonged. These aberrant action potentials are reproduced at multiple anatomic levels: from the primary sensory neuron, to the sensory ganglia, and neurons within the dorsal horn of the spinal cord (Fig. 12-1). Such a pattern of aberrant nerve discharges may account for the positive symptoms of neuropathic pain. The cognizant perception of painful symptoms is based on the neural pathways commencing in the periphery at the primary sensory nerve ending, transmitted through the dorsal root ganglia, the spinal cord, up to the thalamus and finally the somatosensory parietal cerebral cortex (Fig. 12-2). During the passage of nerve potentials along this pathway, a number of opportunities are available at the various synapses for modulation of the impulses per se and thus the eventual perception of the original stimulus.

When chronic pain syndromes develop, there is evidence to support the conjecture that different ion channels are involved in both remodeling and ectopic neuronal signaling. The variability in symptomatology as well as the response to pharmacologic treatment may depend on the specific type of channel involved. An example of this correlation is the expression of the acid- and heat-sensitive capsaicin/vanilloid receptor (TRPV1) in nociceptive C-fibers. Inflammation and focal tissue acidity following nerve injury may activate this receptor, enhancing exaggerated pain responses. On the other hand, continuous activation of this receptor may desensitize these fibers and account for the analgesic efficacy of capsaicin.

In addition, an alteration of central nervous system signal transduction also occurs in some patients suffering from neuropathic pain. Following nerve injury, retrograde transport of growth factors from the distal neuron to the cell body is impaired or lost. Disruption of intercellular signaling cascades causes structural changes in second- and third-order neurons, altering the expression of neuromodulators such as brain-derived natriuretic factor and substance P in nociceptive A-fibers. Simultaneously, ectopic activity and injury discharge may cause preferential death of inhibitory interneurons located in the superficial laminae of the dorsal horn. These changes ultimately lead to decreased inhibition of pain signaling within the spinal cord. In addition to changes in inhibitory pathway signaling, the preferential loss of C-fiber neurons as observed in animal models may lead to remodeling of synaptic architecture. Following denervation, A-fiber neurons from deep laminar loci sprout new afferents to form functional synapses in portions of the spinal column formerly occupied by C-fiber termini. This expansion of neuronal receptive fields may play a key role in the zones of hyperalgesia adjacent to the territory of primary nerve injury.

Diagnosis and Clinical Manifestations

The diagnosis of neuropathic pain syndromes requires a thorough exam and careful consideration of a patient’s medical history. Neuropathic pain symptoms are distinct from nonneuropathic (nociceptive) pain. The following criteria have been proposed to define and differentiate neuropathic pain from nociceptive pain:

Using this schema, there are four forms of pain that are characterized by positive sensory phenomena:

In contrast, negative phenomena refer to loss of sensation. Differences in quality and spatial characteristics of pain symptoms may also be used to distinguish neuropathic pain from nonneuropathic pain, with symptoms of stimulus-evoked pain, shooting pain, electric shock, burning, and cold significantly more common in patients with neuropathic pain. Neuropathic pain also tends to be perceived as a superficial sensation, whereas other forms of pain are felt in deeper tissues, muscles, and joints. Motor as well as other nonsensory neurologic symptoms may also occur in neuropathic pain syndromes. These include weakness, spasticity, tremor, ataxia, apraxia, spasticity, hypotonia, muscle spasms, and muscle tenderness. The concordance of these nonsensory symptoms with positive and negative phenomena is strongly suggestive of the presence of a neuropathic pain syndrome.

The quality, intensity, and duration of symptoms should always be carefully assessed in any chronic pain patient, and the characteristics and distribution of aberrant sensory phenomena can be used to guide the focused neurologic examination. Standard neurologic physical exam tools such as cotton wisps, tuning forks, and warm and cold objects may be used to evaluate evoked pain and, when coupled with a thorough neurologic examination, may help to localize the lesion. In the presence of confirmatory history and laboratory data, positive and negative phenomena (evoked or spontaneous) occurring in the territory of a localized lesion confirms the clinical diagnosis.

In addition to the history and physical examination, ancillary studies may aid in diagnosis. These are very important for confirming or excluding the presence of underlying etiologies for neuropathic pain. Magnetic resonance imaging is used to assess the integrity of central neuroanatomic structures involved in pain signaling pathways. These include the spinal cord, brainstem, thalamus, and cortices (see Fig. 12-1). Peripheral sources for the pain can sometimes be defined by electromyography and nerve conduction studies. The latter particularly assess the function of large myelinated nerve fibers. Nonneurologic tests such as oral glucose tolerance, Tzanck prep (a rapid test previously performed to diagnose infections caused by herpes viruses) and enzyme-linked immunosorbent assay. This can be used to confirm or exclude the presence of a number of underlying diseases that may lead to sequelae of neuropathic pain. Psychiatric evaluation is also useful in evaluating possible somatization disorders in patients with multisystem complaints that may date back into early developmental stages.

Treatment

Gauging the efficacy of treatment protocols represents a significant challenge in the treatment of neuropathic pain. Severity of pain is typically assessed at the time of exam, as well as over short time intervals, and subjectively graded by the patient on the 0–10 numeric rating scale, with a score of 0 representing “no pain” and a score of 10 representing “worst possible pain.” Research suggests that clinically important pain relief is achieved with a 30% reduction in score on this scale, corresponding to a categoric rating of “moderate relief” or “much improved.” In addition, counseling patients and families about reasonable expectations for symptom improvement is crucial. Patients must understand that partial reduction in pain intensity is the norm with pharmacotherapy. Furthermore, successful treatment will require a program of adaptive coping by the patient per se. A comprehensive approach that calls on close monitoring of side effects of medications used to treat neuropathic pain is essential, as many of these drugs have significant adverse events, especially when used in older patients.

First-Line Prescription Agents

These include topical lidocaine, calcium channel α2-δ ligands (gabapentin, pregabalin), tricyclic antidepressants (TCAs) and serotonin norepinephrine reuptake inhibitors.

Putative calcium channel ligands such as gabapentin inhibit presynaptic calcium channel α2-δ subunits activity in the superficial laminae of the dorsal horn of the spinal cord. Their exact site of action within the central nervous system as antiepileptic agents and for their other benefits remains unclear.

Tricyclic antidepressants historically are thought to modulate pain signaling by affecting both serotonergic and noradrenergic reuptake in descending inhibitory supraspinal pathways (Fig. 12-3). Desipramine and nortriptyline are preferred for neuropathic pain because of their favorable side-effect profiles relative to amitriptyline. Although their anticholinergic side effects demand careful consideration when these are used in patients with comorbidities, TCAs will relieve pain in PHN, postmastectomy pain syndrome, and painful diabetic neuropathy (PDN) and nondiabetic peripheral neuropathy. These agents should be tried alone initially, and then may be used in combination to pursue symptomatic improvement if necessary, provided that the clinician carefully monitors their interactions and side effects.

Lidocaine preferentially inhibits voltage gated sodium channels in neuronal regions undergoing more frequent depolarization. It effectively suppresses ectopic impulses that develop following neuronal injury and the subsequent increase in sodium channel production and propagation at the affected site. This selectivity allows lidocaine to be safely used at low enough doses that avoid disrupting normal impulse conduction while still suppressing hyperexcitability. Infusion has proven an efficacious route for delivery in the treatment of both PHN and DPN (diabetic polyneuropathy), but its use is limited because of dosing and delivery issues arising with intravenous administration. Lidocaine is mainly used in the 5% patch form for the treatment of PHN and, in contrast, has a low probability for drug interactions and systemic side effects.

Opioid analgesia (Fig. 12-4) is considered by many experts to be a first-line agent as well, although considerable debate surrounds its role in management of neuropathic pain because of issues of tolerability, long-term efficacy, and the risks of misuse and abuse. Multiple trials support the use of these various pharmacologic modalities in chronic conditions such as PDN and PHN with evidence of superior efficacy and reduced side-effect burden when prescribed in combination with a calcium channel modulator. In clinical trials, opioid side effects, including nausea, sedation, and constipation, contributed to significant patient dropout, despite reported reductions in pain. Tramadol exerts its analgesic effects through both opioid and descending inhibitory pathways; it has been shown to be effective in reducing pain associated with nerve injury and improving quality of life.

A Ten-Step Process for opioid therapy utilized over the long term has been suggested by the International Society of Interventional Pain Physicians (Box 12-1). This provides the clinician with responsible guidelines for maintaining careful control of a potentially very useful therapeutic modality.

Painful Diabetic Neuropathy

Clinical Vignette

Julia, a 53-year-old woman, presents complaining of burning pain in her lower extremities. The pain started 18 months earlier beginning in her toes and has progressively ascended to involve her feet to the ankles bilaterally. She describes the pain as a persistent burning and tingling throughout the day, stating that her feet feel like “they’re asleep all the time,” and says the pain is worse at night. Her past medical history is significant for type 2 diabetes mellitus diagnosed 5 years prior for which she takes oral medications, including metformin and a glitazone. When questioned, she describes a pattern of poor medication compliance, erratic home blood glucose values, and denies performing regular foot inspections.

On exam, her muscle strength, patellar muscle stretch reflexes, and proprioceptive sensation as well as pedal pulses are normal, but she demonstrates diminished light tough, pinprick, and vibratory sensation below the mid-calf bilaterally and absent ankle muscle stretch reflexes. She had an antalgic (painful gait) and had recently been fitted with a prosthetic boot. She also has an asymptomatic plantar ulcer surrounded by callus on the first metatarsal head of the right foot, of which she denies knowledge.

Laboratory values are significant for an HbA1C of 8.7% and creatinine of 1.1, but are otherwise normal. Nerve conduction studies (NCS) demonstrate no abnormalities, including detailed sensory nerve testing. However, these studies did not exclude a small-fiber sensory neuropathy as these unmyelinated type C fibers cannot be separately distinguished from the large-fiber responses with standard NCS.

Pathophysiology

The pathophysiology of PDN is complex, involving an imperfectly understood interaction of metabolic and vascular factors present in diabetes mellitus. Hyperglycemia and increased flux through the polyol pathway leads to intracellular accumulation of sorbitol and fructose, with reduction in Na+/K+-ATPase activity, as well as the accumulation of nonenzymatic advanced glycation end products on neural and vascular proteins. These metabolic derangements, coupled with protein kinase C activation, derangements in fatty acid metabolism, and oxidative stress driven by hyperlipidemia and hyperglycemia are responsible for gradual damage and impairment of microvascular endothelial function. Hypoperfusion follows, with hyalinization and maladaptive hyperplasia of microvascular vasa nervorum accounting for progressive dysfunction of both small and large nerve fibers. This hypoxia also damages small unmyelinated fibers innervating arterioles responsible for arteriovenous shunting in endoneurium and perineurium, further exacerbating ischemic nerve injury. Patients experiencing painful symptoms also demonstrate neovascularization on the surface of nerves in affected regions, mirroring hypoxia-induced neovascularization seen in diabetic retinopathy. This expansion of vascular territories may lead to a hyperperfusion state, with paradoxically less hypoxia in painful neuropathy and, although poorly understood, suggests a hemodynamic etiology to the development of painful symptoms in diabetic polyneuropathy.

Treatment

The mainstay of treatment in painful diabetic polyneuropathy is proper glycemic control targeting an HbA1C at or below 6.5%. Although intense diabetes management cannot completely arrest the development of neuropathy, it has been shown to significantly delay the onset of symptoms in type 1 diabetes and may have some benefit in type 2 diabetes.

Symptomatic treatment of pain is a mainstay of diabetic neuropathy management, as it has significant impact on quality-of-life issues such as sleep and daily comfort. The assessment of symptoms per se and communication regarding treatment outcome expectations is the first step in managing any chronic neuropathic pain syndrome, followed by prescription of a first-line pharmaceutical agent. Among the first-line agents previously reviewed, the serotonin–norepinephrine reuptake inhibitor duloxetine has shown particular promise in PDN, demonstrating superior efficacy compared to placebo (number needed to treat [NNT] = 4.9–5.3) and comparable safety compared to standard care (gabapentin, amitriptyline, and venlafaxine) in a number of double-blind clinical trials. Duloxetine’s frequent side effects included nausea, somnolence, dizziness, reduced appetite, and dry mouth. This is started at 30 mg/day and titrated to 60–120 mg/day after 4–5 days to minimize side effects. TCAs may also be used to treat painful diabetic polyneuropathy, with relatively lower NNTs compared to other agents (amitriptyline, 2.1; desipramine, 2.2; imipramine, 1.3; clomipramine, 2.1; and nortriptyline with fluphenazine, 1.2.)

Dosage of these agents begins at 10 mg/day and can be titrated upward to 150 mg/day as needed. Gabapentin and pregabalin may also be used at dosage ranges of 900–3600 mg/day and 300–600 mg/day, respectively, with NNTs of 3.8 and 5.9 and maximum dose. Oxycodone may also be used adjunctively in pain-resistant standard pharmacotherapy, but careful consideration of the risks and benefits should be undertaken prior to initiation because of the potential for dependence and abuse.

Complex Regional Pain

Pathophysiology

Although the precise pathophysiology of CRPS remains imperfectly understood, a number of studies have advanced promising and increasingly well-developed theories. Some evidence indicates that diminished sensory input, reduction of central modulation, or end organ hypersensitivity results in increased sympathetic nervous system activity following injurious stimuli. These changes may be caused by impaired transport of nerve growth factors by damaged axons or by alterations in the membrane channel populations following nerve injury. A number of studies support the assertion that catecholamine sensitivity develops in peripheral cutaneous and deep tissue nociceptors following nerve injury.

Expansion of neuronal fields may also occur after peripheral nerve injury, with formation of artificial synapses between somatic and sympathetic fibers, dorsal root ganglia resulting in autonomic dysfunction, and aberrant sources of pain signaling. Supporting this theory is the fact that sympathetic blockade may sometimes alleviate pain symptoms, although there is tremendous variability in clinical response to these treatments.

Loss of nociceptive small-fiber axons following nerve injury may also contribute to CRPS. Limited studies have demonstrated a 30% reduction in neurite density of skin biopsies compared to ipsilateral control sites in patients experiencing allodynia and hyperalgesia at CRPS-affected sites, strongly supporting this theory. Disproportionate inflammatory reaction following injury may occur, with free radical damage to tissues, anoxia, and subsequent dysregulation of vascular function and blood flow. Langerhans cell proliferation following denervation has also been documented, suggesting a significant inflammatory component in CRPS. Proinflammatory and chemotactic cytokines TNF-α, IL-1, and IL-6 released from these cells may play a role in the exaggerated local inflammatory response as well as the trophic changes in nails, hair, and bony tissues.

Although psychological influences in the development of CRPS have been postulated, current evidence increasingly suggests that psychological symptoms are more likely secondary to the syndrome rather than the primary cause. Overall, characterization of pathophysiological factors contributing to the development of CRPS is in its infancy, and further research is an area of high priority.

Clinical Features and Diagnosis

The major clinical features of CRPS are spontaneous pain, allodynia, hyperalgesia, edema, vasomotor instability, autonomic dysfunction, and progressive trophic changes. CRPS occurs as two subtypes, with the presence of an identifiable noxious stimulating event delineating between the two. Type I CRPS develops in the absence of an identifiable focal nerve lesion, whereas type II CRPS occurs in the presence of identifiable nerve damage. CRPS has historically been considered a multiphasic disorder, with an early “acute” phase characterized by vasomotor instability and edema, a late “atrophic” phase defined by atrophy and contracture, with an intermediate phase between the two. More recent research, however, suggests that the different symptoms of CRPS are more likely variant subtypes as opposed to stages of the disease. The vast majority of CRPS patients experience only the “acute” phase symptoms, typically with spontaneous resolution over time, and only 2% go on to develop the atrophic symptoms associated with chronic CRPS.

The predominant features of CRPS are pain symptoms such as allodynia, hyperalgesia, and spontaneous sensations of burning, shooting, aching, or other discomfort. The pain is typically experienced in a distribution beyond the initially affected nerve(s) and may spread to involve the entire affected limb and, rarely, the contralateral limb as well. These symptoms are generally constant in nature and frequently worsen over time, leading to significant impairment of quality of life and psychological distress.

Additionally, sympathetic dysfunction is present, mediating pain symptoms as well as autonomic instability (see Fig. 12-7). Patients may initially experience a warm, anhydrotic, edematous extremity with progression to a cold, hyperhidrotic limb and resolving edema. Trophic changes in the affected limb also occur, with hypertrophic or atrophic hair and nail growth and degeneration of the skin and subcutaneous fat. Connective tissues may become adherent to each other, leading to contractures and loss of function in the affected extremity. Rapid bone loss also develops, resulting in demineralization and osteoporosis. Finally, weakness, tremor, and other motor anomalies may occur in the affected extremity, with profound loss of function.

Diagnosis of CRPS is a clinical one; there are no specific diagnostic tests for CRPS. When the typical symptoms of CRPS occur in the context of surgery, fracture, or other noxious stimulus, these are very suggestive of the diagnosis. Initially one must exclude various primary neurologic, infectious, and autoimmune etiologies. Plain bony radiographic testing may help to demonstrate unilateral demineralization and cortical erosions suggestive of CRPS, and Tc 99m-labeled bisphosphonate bone scan techniques demonstrate an 80% sensitivity and specificity in detecting osseous changes typical of CRPS.

Infrared thermography demonstrating greater than 1°C difference in temperature between the affected and contralateral extremity is 93% sensitive and 89% specific in the diagnosis of CRPS, although it is rarely employed because of the specialized equipment required. In patients simultaneously experiencing severe pain and sympathetic dysfunction, stellate ganglion and lumbar paravertebral sympathetic blocks have also been used to diagnose and treat CRPS, with greater than 50% reduction in pain considered significant enough to warrant this diagnosis. However, more recent studies show that sympathetic block is neither sensitive nor specific. Nevertheless, some clinicians still perform this procedure because of the dual prospect of diagnosis and treatment coupled with low morbidity when performed by skilled professionals. Ultimately, the diagnosis of CRPS remains challenging, and further research is warranted because of its marked limitation in the patient’s ability to carry on activities of daily living (ADLs).

Treatment

This requires a multidisciplinary approach to managing symptoms and preserving function. Progressive pain and loss of function account for significant morbidity in these patients, and especially in cases of chronic CRPS. Psychological interventions merit consideration for developing adaptive coping modalities for the affected patient. Symptom management is divided into two broad categories, pharmacotherapy and interventional therapy.

Pharmacotherapy includes several classes of agents, including neuropathic drugs, opioids, bisphosphonates, ketamine, and calcitonin. A large range of neuropathic agents are used to treat CRPS, including TCAs, calcium channel α2-δ ligands, tramadol, and local anesthetics. These have had a varying success.

Amitriptyline is perhaps the most frequently prescribed of these agents, with dosage starting at 10 mg and titrating upwards to a target of 75 mg QHS. In part because of the complexity of CRPS classification and symptoms, prospective studies of these agents are lacking or are very limited, and further characterization is needed. The bisphosphonate alendronate 40 mg/day has been shown in a small trial to improve joint mobility, pain, and hyperalgesia in patients with CRPS through unclear mechanisms.

Ketamine acts as an NMDA antagonist, and is reported to demonstrate promise in the treatment of CRPS. However, larger studies evaluating optimal dosing and duration are needed. Initial retrospective studies have shown drastic reductions in subjective pain scores following subanesthetic ketamine infusion, with a number of patients remaining pain free beyond 3 years after multiple infusions. A further open-labeled study at anesthetic doses of ketamine over 5 days demonstrated complete symptom relief in 79% of patients at 6 months and significant pain relief in all patients who did experience relapse.

A number of interventional therapeutic approaches to CRPS have been studied. Local anesthetic sympathetic blockade is accomplished by infiltrating an agent such as lidocaine in the vicinity of the stellate ganglion for upper-extremity CRPS or the lumbar sympathetic chain for lower-extremity CRPS. This technique aims to address both autonomic and somatic symptoms by disrupting the sympathetic-afferent coupling postulated to account for CRPS symptoms. Although previously considered the gold standard in the treatment of CRPS, clinical study of these techniques has been complicated by difficulty with blinding, variations in technique, and small numbers of patients. The benefit of these techniques is often of limited duration. These may be optimized when used in conjunction with physiotherapy to improve functional status and strength. With a similar therapeutic rationale, sympathetic denervation has also been used in the treatment of CRPS. Only one third of patients undergoing surgical sympathectomy report persistent symptom relief at 5 years. These procedures are associated with major side effects, including increased neuropathic symptoms, spinal cord injury, and Horner’s syndrome.

Spinal cord stimulation has also shown promise for treatment of CRPS. However, further study of its long-term benefit and improved methods of identifying the subpopulation of patients most likely to benefit are needed. Recent studies demonstrate that the initial high cost of these systems may be offset over the long term if medication and other utilizations are reduced. Spinal cord stimulation may improve ADL not only by reducing pain, but improving other domains of function impaired by CRPS.

Physiotherapy is also considered a first-line therapy in the treatment of CRPS, with aggressive range-of-motion and strengthening exercises shown to improve pain symptoms and reduce overall disability. Careful attention to initial pain management before beginning physiotherapy is very important to make it possible for the patient to physically participate. This underscores the importance of a multimodal approach to CRPS management.